Recently, Sinovac’s influenza vaccine has officially received marketing authorization from the health regulatory authorities of the United Arab Emirates (UAE), marking a significant milestone in the company’s international expansion. This approval allows the vaccine to be legally distributed and administered in the UAE, offering local residents an effective tool against seasonal influenza.Sinovac’s flu vaccine is an inactivated vaccine suitable for individuals aged six months and older, with a well-established safety profile and strong immunogenicity. The vaccine formulation is updated annually based on the World Health Organization’s (WHO) recommended influenza virus strains to ensure optimal protection against circulating seasonal variants. Clinical studies and real-world use across multiple countries have consistently demonstrated the vaccine’s reliability and consistent quality.As a key healthcare hub in the Middle East, the UAE maintains a stringent and internationally aligned regulatory framework. This approval reflects the UAE’s confidence in the quality and safety of Sinovac’s vaccine and paves the way for broader market access in the Middle East and beyond. Going forward, Sinovac may deepen collaboration with the UAE through local partnerships, technology transfer, or joint production initiatives, strengthening global public health cooperation in combating infectious diseases.
近日，中国科兴公司研发的流感疫苗正式获得阿拉伯联合酋长国（阿联酋）卫生监管部门的注册批准，标志着该疫苗在国际市场拓展方面取得重要进展。此次获批意味着科兴流感疫苗可在阿联酋境内合法销售和使用，为当地居民提供针对季节性流感的有效预防手段。科兴流感疫苗是一种灭活疫苗，适用于6月龄及以上人群，具有良好的安全性和免疫原性。该疫苗根据世界卫生组织（WHO）每年推荐的流感病毒株进行更新，以匹配当季流行毒株，从而提升保护效果。在多个国家和地区的临床研究与实际应用中，科兴流感疫苗均表现出稳定的质量和可靠的防护能力。阿联酋作为中东地区重要的医疗健康枢纽，其药品监管体系严格且国际化程度高。此次获批不仅体现了阿联酋对科兴疫苗质量与安全性的认可，也为中国疫苗企业进一步开拓中东及全球市场奠定了基础。未来，科兴有望通过本地合作、技术转移或联合生产等方式，深化与阿联酋及其他国家在公共卫生领域的合作，共同应对全球传染病挑战。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/20132.html